"Overall, Life Sciences revenue was up 42% organically year-over-year, and we added more than 300 customers, a reinforcement that not only are our offerings attractive but also paving the foundation for more future growth as our business increases at these new accounts.
In Life Science Services, revenue was $80 million, up 28% year-over-year with growth delivered from each of the sub-segments. We once again delivered record revenue quarters in each of our three major sub-segments of genomic services, NGS, synthesis and Sanger Sequencing.
Next-generation sequencing was up nearly 60% year-over-year. This service offering continues to grow as a result of our highly skilled NGS case teams, which engage customers early in the experimental design and follow through from there to data. In the quarter, we launched the full complement of capabilities of NGS solutions for gene therapy applications, and this capability has already attracted 20 biopharma and biotech customers in the US alone.
The Synthesis business delivered another solid growth quarter, up 33% from Q3 last year. This steady and significant growth comes from pharma and biotech customers. We continue to build out capacity to stay in front of what we see as a sustained healthy demand environment.
The Sanger business came in at $15 million, up 72% against a weak Q3 2020, but it was another all-time record and quite meaningfully up 10% sequentially, which is a particularly strong sequential growth indicator compared to what was also a record prior quarter."
Looks like revenue of the semi business grew 47 percent y-y also. |
